Skip to content

Janux Therapeutics JANX Contract Liabilities

Contract Liabilities at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
$79M-72.9%

Other financials

Income statement

See full
Revenue$3.7M
Operating income-$34.2M+2.0%
Net income-$24.4M-3.6%
EPS (diluted)-$0.39-2.6%

Balance sheet

See full
Cash & equivalents$51.8M-29.7%
Total debt$21.6M-4.6%
Total equity$941.5M-7.0%
Total assets$1.0B-2.1%

Cash flow

See full
Operating cash flow-$12.3M+27.5%
CapEx$273.0K-26.4%
Free cash flow-$12.6M+27.5%

Valuation

See full
Market cap$889.15M-36.3%
Enterprise value$858.89M-36.2%
P/S64.8×-84.8×

Profitability

See full
Operating margin-1,143.1%-65.1pp
Net margin-833.6%+0.9pp
FCF margin-571.6%+98.3pp

Returns & leverage

See full
Return on equity-11.7%+4.1pp
Debt / equity0.0×
Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Janux Therapeutics's contract liabilities?
Janux Therapeutics (JANX) reported contract liabilities of $8.68M in Q1 2026.
What is the long-term trend for Janux Therapeutics's contract liabilities?
Over 4 years (2020 to 2025), Janux Therapeutics's contract liabilities has grown at a -100.0% compound annual growth rate (CAGR), from $6.05M to $0.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.